Global Linagliptin DPP-4 Inhibitors 麻豆原创 Growth 2025-2031

Publication ID:

LPI06253232

Publication Date:

June 19, 2025

Pages:

118

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Linagliptin DPP-4 Inhibitors market size is predicted to grow from US$ 485 million in 2025 to US$ 732 million in 2031; it is expected to grow at a CAGR of 7.1% from 2025 to 2031.
Linagliptin is an oral antidiabetic drug that belongs to the class of Dipeptidyl Peptidase-4 (DPP-4) inhibitors. It is used to lower blood sugar levels in adults with Type 2 Diabetes Mellitus (T2DM) by increasing the levels of incretin hormones, which help regulate insulin secretion and glucose metabolism.
United States market for Linagliptin DPP-4 Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Linagliptin DPP-4 Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Linagliptin DPP-4 Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Linagliptin DPP-4 Inhibitors players cover Boehringer Ingelheim, Torrent Pharmaceuticals, Eli Lilly, Mankind Pharma, Alkem Labs, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
publisher, Inc. (LPI) ' newest research report, the 鈥淟inagliptin DPP-4 Inhibitors Industry Forecast鈥� looks at past sales and reviews total world Linagliptin DPP-4 Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Linagliptin DPP-4 Inhibitors sales for 2025 through 2031. With Linagliptin DPP-4 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Linagliptin DPP-4 Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Linagliptin DPP-4 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Linagliptin DPP-4 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Linagliptin DPP-4 Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Linagliptin DPP-4 Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Linagliptin DPP-4 Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Linagliptin DPP-4 Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Original Drug
Generic Drug
Segmentation by Application:
Hospital
Retail Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Boehringer Ingelheim
Torrent Pharmaceuticals
Eli Lilly
Mankind Pharma
Alkem Labs
Zydus
Yangzijiang Pharmaceutical Group
Cspc Holdings Company
Sichuan Kelun Pharmaceutical
Huahai Pharmaceutical
Chengda Pharmaceuticals
China Resources Shuanghe Pharmaceutical
MINSHENG PHARMACEUTICAL
Jiangsu Deyuan Pharmaceutical
Shandong Lukang Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Linagliptin DPP-4 Inhibitors market?
What factors are driving Linagliptin DPP-4 Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Linagliptin DPP-4 Inhibitors market opportunities vary by end market size?
How does Linagliptin DPP-4 Inhibitors break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Linagliptin DPP-4 Inhibitors Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Linagliptin DPP-4 Inhibitors by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Linagliptin DPP-4 Inhibitors by Country/Region, 2020, 2024 & 2031
2.2 Linagliptin DPP-4 Inhibitors Segment by Type
2.2.1 Original Drug
2.2.2 Generic Drug
2.3 Linagliptin DPP-4 Inhibitors Sales by Type
2.3.1 Global Linagliptin DPP-4 Inhibitors Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Linagliptin DPP-4 Inhibitors Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Linagliptin DPP-4 Inhibitors Sale Price by Type (2020-2025)
2.4 Linagliptin DPP-4 Inhibitors Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.5 Linagliptin DPP-4 Inhibitors Sales by Application
2.5.1 Global Linagliptin DPP-4 Inhibitors Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Linagliptin DPP-4 Inhibitors Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Linagliptin DPP-4 Inhibitors Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Linagliptin DPP-4 Inhibitors Breakdown Data by Company
3.1.1 Global Linagliptin DPP-4 Inhibitors Annual Sales by Company (2020-2025)
3.1.2 Global Linagliptin DPP-4 Inhibitors Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Linagliptin DPP-4 Inhibitors Annual Revenue by Company (2020-2025)
3.2.1 Global Linagliptin DPP-4 Inhibitors Revenue by Company (2020-2025)
3.2.2 Global Linagliptin DPP-4 Inhibitors Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Linagliptin DPP-4 Inhibitors Sale Price by Company
3.4 Key Manufacturers Linagliptin DPP-4 Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Linagliptin DPP-4 Inhibitors Product Location Distribution
3.4.2 Players Linagliptin DPP-4 Inhibitors Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Linagliptin DPP-4 Inhibitors by Geographic Region
4.1 World Historic Linagliptin DPP-4 Inhibitors 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Linagliptin DPP-4 Inhibitors Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Linagliptin DPP-4 Inhibitors Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Linagliptin DPP-4 Inhibitors 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Linagliptin DPP-4 Inhibitors Annual Sales by Country/Region (2020-2025)
4.2.2 Global Linagliptin DPP-4 Inhibitors Annual Revenue by Country/Region (2020-2025)
4.3 Americas Linagliptin DPP-4 Inhibitors Sales Growth
4.4 APAC Linagliptin DPP-4 Inhibitors Sales Growth
4.5 Europe Linagliptin DPP-4 Inhibitors Sales Growth
4.6 Middle East & Africa Linagliptin DPP-4 Inhibitors Sales Growth
5 Americas
5.1 Americas Linagliptin DPP-4 Inhibitors Sales by Country
5.1.1 Americas Linagliptin DPP-4 Inhibitors Sales by Country (2020-2025)
5.1.2 Americas Linagliptin DPP-4 Inhibitors Revenue by Country (2020-2025)
5.2 Americas Linagliptin DPP-4 Inhibitors Sales by Type (2020-2025)
5.3 Americas Linagliptin DPP-4 Inhibitors Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Linagliptin DPP-4 Inhibitors Sales by Region
6.1.1 APAC Linagliptin DPP-4 Inhibitors Sales by Region (2020-2025)
6.1.2 APAC Linagliptin DPP-4 Inhibitors Revenue by Region (2020-2025)
6.2 APAC Linagliptin DPP-4 Inhibitors Sales by Type (2020-2025)
6.3 APAC Linagliptin DPP-4 Inhibitors Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Linagliptin DPP-4 Inhibitors by Country
7.1.1 Europe Linagliptin DPP-4 Inhibitors Sales by Country (2020-2025)
7.1.2 Europe Linagliptin DPP-4 Inhibitors Revenue by Country (2020-2025)
7.2 Europe Linagliptin DPP-4 Inhibitors Sales by Type (2020-2025)
7.3 Europe Linagliptin DPP-4 Inhibitors Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Linagliptin DPP-4 Inhibitors by Country
8.1.1 Middle East & Africa Linagliptin DPP-4 Inhibitors Sales by Country (2020-2025)
8.1.2 Middle East & Africa Linagliptin DPP-4 Inhibitors Revenue by Country (2020-2025)
8.2 Middle East & Africa Linagliptin DPP-4 Inhibitors Sales by Type (2020-2025)
8.3 Middle East & Africa Linagliptin DPP-4 Inhibitors Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Linagliptin DPP-4 Inhibitors
10.3 Manufacturing Process Analysis of Linagliptin DPP-4 Inhibitors
10.4 Industry Chain Structure of Linagliptin DPP-4 Inhibitors
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Linagliptin DPP-4 Inhibitors Distributors
11.3 Linagliptin DPP-4 Inhibitors Customer
12 World Forecast Review for Linagliptin DPP-4 Inhibitors by Geographic Region
12.1 Global Linagliptin DPP-4 Inhibitors 麻豆原创 Size Forecast by Region
12.1.1 Global Linagliptin DPP-4 Inhibitors Forecast by Region (2026-2031)
12.1.2 Global Linagliptin DPP-4 Inhibitors Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Linagliptin DPP-4 Inhibitors Forecast by Type (2026-2031)
12.7 Global Linagliptin DPP-4 Inhibitors Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Boehringer Ingelheim
13.1.1 Boehringer Ingelheim Company Information
13.1.2 Boehringer Ingelheim Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.1.3 Boehringer Ingelheim Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Boehringer Ingelheim Main Business Overview
13.1.5 Boehringer Ingelheim Latest Developments
13.2 Torrent Pharmaceuticals
13.2.1 Torrent Pharmaceuticals Company Information
13.2.2 Torrent Pharmaceuticals Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.2.3 Torrent Pharmaceuticals Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Torrent Pharmaceuticals Main Business Overview
13.2.5 Torrent Pharmaceuticals Latest Developments
13.3 Eli Lilly
13.3.1 Eli Lilly Company Information
13.3.2 Eli Lilly Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.3.3 Eli Lilly Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Eli Lilly Main Business Overview
13.3.5 Eli Lilly Latest Developments
13.4 Mankind Pharma
13.4.1 Mankind Pharma Company Information
13.4.2 Mankind Pharma Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.4.3 Mankind Pharma Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Mankind Pharma Main Business Overview
13.4.5 Mankind Pharma Latest Developments
13.5 Alkem Labs
13.5.1 Alkem Labs Company Information
13.5.2 Alkem Labs Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.5.3 Alkem Labs Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Alkem Labs Main Business Overview
13.5.5 Alkem Labs Latest Developments
13.6 Zydus
13.6.1 Zydus Company Information
13.6.2 Zydus Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.6.3 Zydus Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Zydus Main Business Overview
13.6.5 Zydus Latest Developments
13.7 Yangzijiang Pharmaceutical Group
13.7.1 Yangzijiang Pharmaceutical Group Company Information
13.7.2 Yangzijiang Pharmaceutical Group Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.7.3 Yangzijiang Pharmaceutical Group Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Yangzijiang Pharmaceutical Group Main Business Overview
13.7.5 Yangzijiang Pharmaceutical Group Latest Developments
13.8 Cspc Holdings Company
13.8.1 Cspc Holdings Company Company Information
13.8.2 Cspc Holdings Company Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.8.3 Cspc Holdings Company Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Cspc Holdings Company Main Business Overview
13.8.5 Cspc Holdings Company Latest Developments
13.9 Sichuan Kelun Pharmaceutical
13.9.1 Sichuan Kelun Pharmaceutical Company Information
13.9.2 Sichuan Kelun Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.9.3 Sichuan Kelun Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Sichuan Kelun Pharmaceutical Main Business Overview
13.9.5 Sichuan Kelun Pharmaceutical Latest Developments
13.10 Huahai Pharmaceutical
13.10.1 Huahai Pharmaceutical Company Information
13.10.2 Huahai Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.10.3 Huahai Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Huahai Pharmaceutical Main Business Overview
13.10.5 Huahai Pharmaceutical Latest Developments
13.11 Chengda Pharmaceuticals
13.11.1 Chengda Pharmaceuticals Company Information
13.11.2 Chengda Pharmaceuticals Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.11.3 Chengda Pharmaceuticals Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Chengda Pharmaceuticals Main Business Overview
13.11.5 Chengda Pharmaceuticals Latest Developments
13.12 China Resources Shuanghe Pharmaceutical
13.12.1 China Resources Shuanghe Pharmaceutical Company Information
13.12.2 China Resources Shuanghe Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.12.3 China Resources Shuanghe Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 China Resources Shuanghe Pharmaceutical Main Business Overview
13.12.5 China Resources Shuanghe Pharmaceutical Latest Developments
13.13 MINSHENG PHARMACEUTICAL
13.13.1 MINSHENG PHARMACEUTICAL Company Information
13.13.2 MINSHENG PHARMACEUTICAL Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.13.3 MINSHENG PHARMACEUTICAL Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 MINSHENG PHARMACEUTICAL Main Business Overview
13.13.5 MINSHENG PHARMACEUTICAL Latest Developments
13.14 Jiangsu Deyuan Pharmaceutical
13.14.1 Jiangsu Deyuan Pharmaceutical Company Information
13.14.2 Jiangsu Deyuan Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.14.3 Jiangsu Deyuan Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Jiangsu Deyuan Pharmaceutical Main Business Overview
13.14.5 Jiangsu Deyuan Pharmaceutical Latest Developments
13.15 Shandong Lukang Pharmaceutical
13.15.1 Shandong Lukang Pharmaceutical Company Information
13.15.2 Shandong Lukang Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolios and Specifications
13.15.3 Shandong Lukang Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Shandong Lukang Pharmaceutical Main Business Overview
13.15.5 Shandong Lukang Pharmaceutical Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.